Skip to content
Amelia Bond on 340B's Influence on Biosimilars episode artwork

May 2, 2023 24 min

Amelia Bond on 340B's Influence on Biosimilars

from A Health Podyssey Hosted by Health Affairs

Health Affairs Editor-in-Chief Alan Weil interviews Amelia Bond from Weill Cornell Medical College on her paper exploring whether participation in the 340B drug program influences biosimilar uptake. Bond and coauthors found that in hospital outpatient settings, 340B program eligibility is associated with a lower use of biosimilars and more hospital-based administrations of and revenues from biologics. Order the May 2023 issue of Health Affairs. Currently, more than 70 percent of our content is freely available - and we'd like to keep it that way. With your support, we can continue to keep our digital publication Forefront and podcasts free for everyone. Subscribe: RSS | Apple Podcasts | Spotify | Stitcher | Google Podcasts

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Amelia Bond on 340B's Influence on Biosimilars

0:00 24:09

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of A Health Podyssey?

This episode is 24 minutes long.

When was this A Health Podyssey episode published?

This episode was published on May 2, 2023.

Is there a transcript available for this episode?

Yes, a full transcript is available for this episode. You can read the complete transcript on the episode page.

Can I download this A Health Podyssey episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.